Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Castle Biosciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CSTL
Nasdaq
2834
https://castlebiosciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Castle Biosciences Inc
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
- May 14th, 2024 11:00 am
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"
- May 10th, 2024 11:00 am
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
- May 8th, 2024 8:30 pm
Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know
- May 7th, 2024 1:55 pm
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable
- May 6th, 2024 12:50 pm
Earnings Beat: Castle Biosciences, Inc. (NASDAQ:CSTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
- May 5th, 2024 1:05 pm
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript
- May 5th, 2024 12:32 pm
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
- May 3rd, 2024 11:00 am
Castle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ...
- May 2nd, 2024 9:59 pm
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
- May 2nd, 2024 9:50 pm
Castle Biosciences Reports First Quarter 2024 Results
- May 2nd, 2024 8:05 pm
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
- Apr 30th, 2024 8:30 pm
We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn
- Apr 17th, 2024 11:06 am
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
- Apr 11th, 2024 11:00 am
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
- Apr 10th, 2024 9:00 pm
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
- Apr 10th, 2024 11:00 am
What Makes Castle Bioscience (CSTL) a Prospective Investment?
- Apr 5th, 2024 8:43 am
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
- Apr 4th, 2024 8:30 pm
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 2nd, 2024 11:00 am
Castle Biosciences Announces Updates to its Board of Directors
- Mar 27th, 2024 9:00 pm
Scroll